Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This proposal is based on findings from our previous work involving ferumoxytol-enhanced
cardiac magnetic resonance angiography. The resolution of the pulmonary vasculature based on
our previous imaging protocol was exceptional (PMID: 26786296). In the Partners Healthcare
System between January 1, 2014 and January 1, 2015 there were 541 patients evaluated in
Partners Healthcare-affiliated hospitals with a diagnosis of pulmonary embolism and acute or
chronic kidney disease at the same visit between 01/01/2014 and 01/01/2015. Ventilation
perfusion scanning was performed in 201 patients during this same time interval. Up to 63% of
these patients in one year did not receive the diagnostic test of choice.